Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Open accessThe DOI matches its Crossref record; 68 of the 83 references it cites were found in a registry or an index.
Abstract
The INK4a tumor suppressor locus encodes p16INK4a, an inhibitor of cyclin D-dependent kinases, and p19ARF, an alternative reading frame protein that also blocks cell proliferation. Surprisingly, mice lacking p19ARF but expressing functional p16INK4a develop tumors early in life. Their embryo fibroblasts (MEFs) do not senesce and are transformed by oncogenic Ha-ras alone. Conversion of ARF+/+ or ARF+/- MEF strains to continuously proliferating cell lines involves loss of either p19ARF or p53. p53-mediated checkpoint control is unperturbed in ARF-null fibroblast strains, whereas p53-negative cell lines are resistant to p19ARF-induced growth arrest. Therefore, INK4a encodes growth inhibitory proteins that act upstream of the retinoblastoma protein and p53. Mutations and deletions targeting this locus in cancer cells are unlikely to be functionally equivalent.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the tumour suppressor ARF stabilizes p53, which contributes to the induction of senescence28”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [28]
In the citing paper
“Exposure of MEFs to oxidative stress activates the p19/ARF-p53 pathway, which leads to cellular senescence (Harvey et al., 1993; Kamijo et al., 1997).”
From Single-Cell Transcriptome Analysis Reveals Six Subpopulations Reflecting Distinct Cellular Fates in Senescent Mouse Embryonic Fibroblasts (2020) · cites this paper as Kamijo et al., 1997
In the citing paper
“p19 Arf and, to a lesser extent, p16 Ink4a have been shown to play a role in the activation of cellular senescence and immortalization on passaging of primary mouse cells in culture (26, 43, 44).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [44]
In the citing paper
“whereas oncogenic ras caused neoplastic transformation of the p53DN-expressing cells, as expected (22,29,30)”
From Glycolytic Enzymes Can Modulate Cellular Life Span (2005) · cites this paper as [22]
In the citing paper
“For example, mouse embryonic fibroblasts (MEFs) lacking p53 [72] but not Ink4a (p16) or RB [73,74,75] escape Ras-induced senescence.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [72]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 4,296
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,736
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., & Kastan, M. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7491 · Cited by 1,837
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Self-citationCloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., & Smith, J. R. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1063 · Cited by 1,351
Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Abnormal Centrosome Amplification in the Absence of p53
Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., & Woude, G. F. V. (1996) · Science · doi:10.1126/science.271.5256.1744 · Cited by 797
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
Regulation of p16 CDKN2 Expression and Its Implications for Cell Immortalization and Senescence
Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.859 · Cited by 733
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Zindy, F., Quelle, D. E., Roussel, M. F., & Sherr, C. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201178 · Cited by 574 · cited 2×
“Four previously established MEF cell lines to examine and compare many more animals before included 5-9, 5-10, 6-14 (INK4a, p53 mutant plus wild type), and reaching firm conclusions about the types and frequen6-18 (INK4a, p53 wild type) (Zindy et al., 1997).”
Self-citationTumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
(1993) · PubMed · Cited by 469
Harvey, D. M., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.12b.2375 · Cited by 453
Role of the cyclin-dependent kinase inhibitors in the development of cancer
Hirama, T., & Koeffler, H. (1995) · Blood · doi:10.1182/blood.v86.3.841.841 · Cited by 418
Complex structure and regulation of the P16 (MTS1) locus.
Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H. L., Parry, D., Peters, G., & Kamb, A. (1995) · PubMed · Cited by 383
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis
Kemp, C. J., Wheldon, T., & Balmain, A. (1994) · Nature Genetics · doi:10.1038/ng0994-66 · Cited by 368
Mao, L., Merlo, A. U., Bedi, G. C., Shapiro, G. I., Edwards, C. D., Rollins, B. J., & Sidransky, D. (1995) · PubMed · Cited by 329
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., & Frants, R. R. (1995) · Nature Genetics · doi:10.1038/ng0795-351 · Cited by 310
Hainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C. C., & Montesano, R. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.1.151 · Cited by 298
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280
Monoclonal antibody analysis of p53 expression in normal and transformed cells
Yewdell, J. W., Gannon, J. V., & Lane, D. P. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.444-452.1986 · Cited by 264
Rogan, E. M., Bryan, T. M., Hukku, B., Maclean, K., Chang, A. C.-M., Moy, E. L., Englezou, A., Warneford, S. G., Dalla-Pozza, L., & Reddel, R. R. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4745 · Cited by 250
Kaneko, Y., Yoshida, K., Handa, M., Toyoda, Y., Nishihira, H., Tanaka, Y., Sasaki, Y., Ishida, S., Higashino, F., & Fujinaga, K. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199602)15:2<115::aid-gcc6>3.0.co;2-6 · Cited by 239
Cooperating oncogenes converge to regulate cyclin/cdk complexes.
Lloyd, A. C., Obermüller, F., Staddon, S., Barth, C. F., McMahon, M., & Land, H. (1997) · Genes & Development · doi:10.1101/gad.11.5.663 · Cited by 224
Quelle, D. E., Cheng, M., Ashmun, R. A., & Sherr, C. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.669 · Cited by 220
Self-citationFitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8541 · Cited by 200
Pollock, P. M., Pearson, J. V., & Hayward, N. K. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199602)15:2<77::aid-gcc1>3.0.co;2-0 · Cited by 188
Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Shapiro, G. I., Park, J. E., Edwards, C. D., Mao, L., Merlo, A. U., Sidransky, D., Ewen, M. E., & Rollins, B. J. (1995) · PubMed · Cited by 181
(1996) · PubMed · Cited by 180
Cre-mediated site-specific translocation between nonhomologous mouse chromosomes.
van Deursen, J., Fornerod, M. W. J., van Rees, B. P., & Grosveld, G. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7376 · Cited by 156
Self-citationFrequent Aberrant Methylation of p16INK4a in Primary Rat Lung Tumors
Swafford, D. S., Middleton, S. K., Palmisano, W. A., Nikula, K. J., Tesfaigzi, J., Baylin, S. B., Herman, J. G., & Belinsky, S. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1366 · Cited by 142 · cited 2×
“Neither point mutations within ARF exon 1b nor promoter hypermethylation have so far been detected in tumors or in tumor-derived cell lines (Mao et al., 1995; Merlo et al., 1995; Shapiro et al., 1995; Stone et al., 1995; Fitzgerald et al., 1996; Herzog et al., 1996; Kubo et al., 1997; Swafford et al., 1997; Tanaka et…”
Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds
Walker, G., Hussussian, C., Flores, J. F., Glendening, M. J., Haluska, F. G., Dracopoli, N. C., Hayward, N. K., & Fountain, J. W. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.10.1845 · Cited by 142
The Cat and Mouse Games That Genes, Viruses, and Cells Play
Weinberg, R. A. (1997) · Cell · doi:10.1016/s0092-8674(00)81897-8 · Cited by 138 · cited 1×
“Another property of INK4a nullizygous MEFs is their capacity to be directly transformed by oncogenic ras alleles without a further requirement for collaborating “immortalizing genes,” such as E1a or myc (Serrano et al., 1996; Weinberg, 1997).”
A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies.
Duro, D., Bernard, O., Della-Valle, V., Berger, R., & Larsen, C. (1995) · PubMed · Cited by 130
Murine susceptibility to two-stage skin carcinogenesis is influenced by the agent used for promotion
Reiners, J. J., Nesnow, S., & Slaga, T. J. (1984) · Carcinogenesis · doi:10.1093/carcin/5.3.301 · Cited by 109
Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds.
Holland, E. A., Beaton, S. C., Becker, T. M., Grulet, O., Peters, B. A., Rizos, H., Kefford, R. F., & Mann, G. J. (1995) · PubMed · Cited by 101
p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
Reymond, A., & Brent, R. (1995) · PubMed · Cited by 99
Temperature-Sensitive Mutants of p16CDKN2 Associated with Familial Melanoma
Parry, D., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3844 · Cited by 94
Mutational effects on the p16INK4a tumor suppressor protein.
Yang, R., Gombart, A. F., Serrano, M., & Koeffler, H. P. (1995) · PubMed · Cited by 92
Mutations of the Ki-ras, p53 andAPC genes in adenocarcinomas of the human small intestine
Arai, M., Shimizu, S., Imai, Y., Nakatsuru, Y., Oda, H., Oohara, T., & Ishikawa, T. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970207)70:4<461::aid-ijc14>3.0.co;2-i · Cited by 79
Herzog, C. R., Ev, S., Al, M., Fl, T., Malkinson, A. M., Haugen, A. C., Rw, W., Mw, A., & You, M. (1996) · PubMed · Cited by 66
Association of extended in vitro proliferative potential with loss of p16INK4 expression.
Noble, J. R., Rogan, E. M., Neumann, A. A., MacLean, K. H., Bryan, T. M., & Reddel, R. R. (1996) · PubMed · Cited by 64
Mutations of theINK4aLocus in Squamous Cell Carcinomas of Human Skin
Kubo, Y., Urano, Y., Matsumoto, K., Ahsan, K., & Arase, S. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6217 · Cited by 61
Tanaka, H., Shimada, Y., Imamura, M., Shibagaki, I., & Ishizaki, K. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970207)70:4<437::aid-ijc11>3.0.co;2-c · Cited by 54 · cited 1×
“Neither point mutations within ARF exon 1b nor promoter hypermethylation have so far been detected in tumors or in tumor-derived cell lines (Mao et al., 1995; Merlo et al., 1995; Shapiro et al., 1995; Stone et al., 1995; Fitzgerald et al., 1996; Herzog et al., 1996; Kubo et al., 1997; Swafford et al., 1997; Tanaka et…”
p53 mutations in spontaneously immortalized 3T12 but not 3T3 mouse embryo cells.
Rittling, S. R., & Denhardt, D. T. (1992) · PubMed · Cited by 41
Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
Wick, S. T., Dubay, M., Imanil, I., & Brizuela, L. (1995) · PubMed · Cited by 36
Genetic background and development of skin tumors.
Naito, M., & DiGiovanni, J. (1989) · PubMed · Cited by 36
Stadler, D. R. (1981) · Fungal Genetics Reports · doi:10.4148/1941-4765.1660 · Cited by 13
Research works printed but not linked: 1
- Quelle, 1995, Cloning and characterization of murine p16INK4a and p15INK4b genes, Oncogene, 11, 635
Cited by
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Self-citation
Metadata
- Authors
- Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Corresponding author
- Sherr, Charles J.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1997-11
- Volume
- 91
- Issue
- 5
- Pages
- 649-659
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W1973886069
- Cited by
- 1,566
- References
- 83
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 10 · 2023: 14 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 22 · 2018: 24 · 2017: 31 · 2016: 38 · 2015: 38 · 2014: 49 · 2013: 60 · 2012: 51
- FWCI
- 34.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 5737 d)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-71907, CA21765, P30CA021765, P01CA071907)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- p16INK4a, p19ARF, alternative reading frame, tumor suppression, p53, retinoblastoma protein, cellular senescence, growth arrest, mouse embryonic fibroblasts
- MeSH terms
- Animals, Cell Division, Leukemia, Erythroblastic, Acute, Exons, Female, Humans, Kidney, Male, Mice, Inbred C57BL, Mice, Mutant Strains, Neoplasms, Experimental, Phenotype, Proteins, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, G1 Phase, Mutagenesis, Open Reading Frames, 3T3 Cells, Gene Deletion, Cyclin-Dependent Kinase Inhibitor p16, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.